Stock data
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE) reported net income of -US$38.63M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$54.21M | -US$38.63M | — |
| 2024 | — | — | -US$81.11M | -US$72.70M | — |
| 2023 | — | — | -US$143.31M | -US$135.35M | — |
| 2022 | — | — | -US$112.38M | -US$108.50M | — |
| 2021 | — | — | -US$72.88M | -US$73.96M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$43.40M | — |
| 2026-03-31 | — | -US$44.50M | — |
| 2025-12-31 | — | -US$46.13M | — |
| 2025-09-30 | — | -US$27.08M | — |
| 2025-06-30 | — | -US$12.29M | — |
| 2025-03-31 | — | US$46.88M | — |
| 2024-12-31 | — | US$13.44M | — |
| 2024-09-30 | — | -US$23.86M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.